Processing of fish population by lufenuron

FIELD: veterinary medicine.

SUBSTANCE: drug is applied by oral administration of daily doses of 1 lufenuron to 30 mg/kg of fish biomass within a period of 3 to 14 days, while the total number of lufenuron used during the specified interval of time is from 7 up to 350 mg/kg of fish biomass.

EFFECT: invention is suitable for treating salmon and provides continued effective protection against sea lice in the sea.

10 cl, 6 tbl, 2 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and aims at controlling demodectic mange in cattle. As an insectoacaricide, a composition is used in the following mixture ratio, wt %: abamectin - 0.1; fipronil - 0.5; dimehyl sulphoxide - 10; ethyl cellulose - 30-40; polyethylene glycol - 1,500 - 16; isopropyl alcohol - the rest up to 100. The composition is used by local applications on the affected areas of the animal's skin.

EFFECT: method enables increasing the therapeutic effectiveness in treating demodectic mange in cattle.

1 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: insecticidal-acaricidal agent is used as a composition with the following ratio of components, wt %: abamectin - 0.1; fipronyl - 0.5; dimethyl sulfoxide - 10; ethyl-cellulose - 30-40; polyethylene glycol-1500 - 16; isopropyl alcohol - the rest to 100. The composition is used by the method of application to the region of dewlap, shoulder, hip and abdomen in a dose of 20 ml per animal.

EFFECT: method enables to increase the efficiency of protection of cattle from ixodic ticks.

1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: as the substance, possessing the arcaricidal action, applied is N,N'-(sulphonyldi-p-phenylene)bis-N",N"-dimethylformamidine.

EFFECT: application of the claimed substance assists to deal with ticks and mites in an efficient and safe way.

6 dwg, 8 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to dihydroazol compounds of formula (I) wherein R1 means a C1-C6alkyl or C1-C6haloalkyl; X means a phenyl, which can be unsubstituted or substituted by one or more halogens, C1-C12alkyls, C3-C10cycloalkyls, C1-C12haloalkyls, C2-C12alkenyls, C2-C12haloalkenyls, C1-C12alkinyls or C1-C12haloalkynyls; A1 means hydrogen, and A2 means CR7R8; G means G-1 or G-2; B1, B2, B3, B4 and B5 independently mean N or C-R9; Y means Y-1, Y-2, Y-3, Y-4, Y-5, Y-6, Y-7, Y-8 or Y-9 (as it is presented in the patent claim); R2, R3 independently mean hydrogen, C1-C12alkyl, C1-C12haloalkyl, thio-C1-C12alkyl, C1-C12alkylthio-C1-C12alkyl, hydroxy-C1-C12alkyl, C1-C12alkoxy-C1-C12alkyl, C2-C12alkenyl, C2-C12haloalkenyl, C2-C12alkynyl, C2-C12haloalkynyl, C3-C10cycloalkyl; R4 independently means hydrogen, C1-C12alkyl, C1-C12haloalkyl, thio-C1-C12alkyl, C1-C12alkylthio-C1-C12alkyl, hydroxy-C1-C12alkyl, C1-C12alkoxy-C1-C12alkyl, C2-C12alkenyl, C2-C12haloalkenyl, C2-C12alkynyl, C2-C12haloalkynyl or C3-C10cycloalkyl; R7 and R8 independently mean hydrogen, C1-C12alkyl or C1-C12haloalkyl; R9 means hydrogen, halogen, C1-C12alkyl, C1-C12haloalkyl, C1-C12alkenyl, C2-C12haloalkenyl, C2-C12alkynyl or C2-C12haloalkynyl; each R10, R11, R12 and R13 independently means hydrogen, C1-C12alkyl or C1-C12haloalkyl; or R10 together with R11 form =O, =S or =NR2; or R12 together with R13 form =O, =S or =NR2; n=1. The invention also refers to compositions for treating or preventing endoparasitic infections or ectoparasitic invasions in animals and for protecting crops, plants, planting stock or timber against pests, to a method of treating or preventing endoparasitic infections or ectoparasitic invasions in animals, to a method for protecting crops and growing plants against pest attacks or invasions, to a method for preventing or controlling a pest invasion on site, and to using the compounds of formula (I).

EFFECT: compounds of formula (I) applicable for preventing or treating endoparasitic infections or ectoparasitic invasions in animals, and also as pesticides

30 cl, 2 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: declared group of inventions refers to veterinary science and aims at controlling blood-sucking parasites and consuming parasites. The composition contains an antiparasitic effective subtoxic amount of imidacloprid in a single dose making 0.25 mg/kg to 30 mg/kg for oral delivery. Imidacloprid is the only antiparasitic being an ingredient of the composition. What is declared is using the above composition. The subtoxic amount of imidacloprid in a single dose makes 0.25 mg/kg to 30 mg/kg. The infestation is eliminated within 1-72 hours after administration of the single dose.

EFFECT: declared group of inventions provides effective elimination of blood sucking parasites and blood consuming parasites.

24 cl, 6 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of calves with Simuliidotoxicosis is that 40% solution of urotropine is administered intravenously to calves at a dose of 1.5 ml per 10 kg of animal body weight.

EFFECT: improvement of efficiency of the method.

Anthelmintic agent // 2521335

FIELD: veterinary medicine.

SUBSTANCE: anthelmintic agent for treatment and prevention of helminthoses in domestic and wild ruminants, characterised in that it comprises ivermectin and sodium chloride in a ratio of 0.1:99.9, and is made in the form of the salt briquettes weighing 5 kg and 10 kg for unrestricted animal feeding. The anthelmintic agent is convenient to use for domestic and wild animals, as it does not require their fixing.

EFFECT: increased efficiency of agent and its reduced toxicity, reduction of cost of treatment and prevention.

2 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of arachnomyiasis of animals comprises administering to them of ivermectin, which is used in the form of salt briquettes comprising ivermectin and sodium chloride in a ratio of 0.1:99.9. The briquettes are laid out in the troughs at the rate of 0.2 mg/kg of ivermectin for voluntary licking by animals for 14 days.

EFFECT: high insect-acaricide action, good tolerability, increased bioavailability and activity of the active substance, exclusion of stress of animals, reducing costs for processing, improved efficiency, reduced toxicity and costs for treatment.

3 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition used in treating new growths and containing: artemisinin, artemether, arteether, artenimol or artesunate and a pharmaceutically acceptable excipient specified in a group consisting of: medium-chain triglycerides, short-chain triglycerides; omega-3-marine triglycerides; and cod liver oil high in omega-3-fatty acids wherein the above composition is presented in the form of a preparation for transmucosal, sublingual, buccal or nasal dosage.

EFFECT: provided high bioavailability and stability; prevented self-induction.

15 cl, 11 tbl, 14 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science, and may be used in veterinary science in treating parasitic skin diseases in animals caused by itch mites. An agent for itch mite treatment in veterinary science contains a quaternary phosphonium salt, substituted dinitrobenzofuraxan, xymedon hydrochloride and dimethylsulphoxide in weight ratio 0.1:1:10:100. The treatment uses 1% emulsion of the given agent in dimethylsulphoxide.

EFFECT: agent is non-toxic and possesses the high acaricidal efficacy after two administrations every 7-10 days.

4 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of structural formula I

which can be used for protecting cardiomyocytes or for preventing or treating a disease or a disorder related to cardiomyocyte apoptosis. In formula I A represents =S, -SR4 or =O, X represents F, Cl, Br or I, R1 represents phenyl, R2 and R3 are connected to form morpholine, and R4 represents C1-C6-alkyl.

EFFECT: invention refers to using the compound for producing the therapeutic agent for protecting cardiomyocytes or for preventing or treating a disease or a disorder related to cardiomyocyte apoptosis, and to the method for producing the above compounds.

8 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, and represents a pharmaceutical composition in the form of gel, which contains clindamycin phosphate, a combination of gel-forming polymer and hydrophilic dispersion phase, pH control agent, allantoin and lauryliminodipropionate sodium tocopheryl phosphate; the ingredients of the composition are taken in certain ratio, in g per 100 g.

EFFECT: invention provides the high level of antibacterial activity and stability.

5 cl, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to optic isomers of (+)- and (-)-1-[(3- chlorophenyl)-phenyl-methyl]urea, to based on them pharmaceutical composition, possessing anti- convulsive activity, as well as to method of obtaining said isomers. Method is realized by interaction of racemic mixture of respective benzhydrylamine with tartaric acids in organic solvent with obtaining diastereomers of benzhydrylamine tartrates, which further react with cyanates of alkali metals in water solution with obtaining isomers (+)- and (-)-1-[(3-chlorophenyl)-phenyl-methyl]urea.

EFFECT: optic isomers, possessing different strength of therapeutic activity and method of their obtaining.

10 cl, 1 dwg, 4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: present group of inventions refers to medicine, namely to neurology and cardiology, and concerns treating a complication related to an aneurysmal subarachnoidal haemorrhage. That is ensured by determining the patient's plasma citrulline, and if observing a decrease thereof, an effective amount thereof is administered.

EFFECT: method provides effective treatment of such complication as the vasospasm by increasing the nitrogen oxide level.

16 cl, 1 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound presented by formula

,

wherein A1 means benzene or heterocycle specified in a group consisting of pyridine, pyrazine, imidazole, thiazole, pyrimidine, thiophen, pyridazine, benzoxazine and oxobenzoxazine; A2 means benzene, if needed substituted by fluorine, or thiophen; B1 means hydrogen, lower alkyl, if needed substituted by piperazinyl or morpholino, halogen-substituted lower alkyl, lower alkoxy substituted by carbamoyl, acylamino, carbamoyl or lower alkylcarbonyloxy (provided A1 means thiazole, B1 does not mean acylamino); B2 means hydrogen or a functional group containing at least one nitrogen atom specified in a group consisting of acylamino, pyrrolidinyl, morpholino, piperidinyl, if needed substituted by acyl, piperazinyl, if needed substituted by lower alkyl or acyl, pyrazolyl, diazabicyclo[2.2.1]heptyl, if needed substituted by acyl, and di-(lower alkyl)amino, if needed substituted by amino or acylamino (provided A1 means thiazole, B2 does not mean acylamino); Y means a group presented by formula

,

wherein J means ethylene or lower alkynylene; L means a bond; M means a bond; X means -(CH2)m-, -(CH2)m-O- or -(CH2)m-NR2- (wherein m is an integer of 0 to 3, and R2 means hydrogen); D means -NR3-, wherein R3 means hydrogen; and E means amino, or its pharmaceutically acceptable salt. The compounds of formula (I) are used for preparing a pharmaceutical agent or a pharmaceutical composition for treating or preventing the VAP-1 related diseases.

EFFECT: benzene or thiophen derivative as a VAP-1 inhibitor.

13 cl, 25 tbl, 125 ex

FIELD: medicine.

SUBSTANCE: method involves a patient's face exposure to full-spectrum natural or artificial light of light intensity not less than 2000 lux for 1-2 hours a day combined with or followed by an exercise load. Additionally, an eating disorder is typed and corrected using psychophysiological techniques. A caloric value of a diet is specified by reducing the patient's regular mean daily energy requirement per a percentage equal to the patient's body weight index with lipid restriction to 40-60 g/day for a period of 6 months with fasting days once every 1-2 weeks. The exercise load is performed in an anaerobic gradual regimen with no weight and resistance on muscle groups of the upper body and waist, with a power load on muscle groups of the lower body until muscular fatigue in the number of 2-3 sets with a rest. They are combined with or followed by a prolonged exercise load at least 4 times a week for 40-60 min in an aerobic regimen with 2-3 acceleration episodes of 3-5 minutes. They are combined with drug-free procedures aiming at improving the regional blood flow, improving the muscular tonus of the anterior abdominal wall and sides, the greater muscle groups of the upper body. If the patient has no insulin resistance syndrome or the sugar blood level less than or equal to 6.1 mmole/l, preparations and biologically active additives containing lipoic acid and vitamin B1 are administered. If the patient suffers from insulin resistance syndrome and/or a fasting glucose level of more than 6.1 mmole/l, the preparations of biguanidines containing metformin are prescribed. Diet mistakes require prescribing preparations of lipase inhibitors containing orlistat.

EFFECT: higher therapeutic effectiveness taking into account a degree of obesity with reducing side effects of therapy.

9 cl, 6 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of general formula (I) or pharmaceutically acceptable salts thereof, where Alk is an C1-C6alkyl group; G is C=O and Q is CR51R52 or NR51, where R51 and R52, being identical or different, independently denote H, C1-C6alkyl, optionally substituted with a substitute selected from a group comprising carboxy, phenoxy, benzyloxy, C1-C6alkoxy or hydroxy; C3-C6cycloalkylC1-C6alkyl; phenylC1-C6alkyl, optionally substituted with a halogen; phenylamidoC1-C6alkyl; phenylC1-C6alkylamidoC1-C6alkyl, optionally substituted with a C1-C6alkoxy group; or R51 and R52, together with a carbon atom with which they are bonded form a C=O or C2-C6alkenyl group, optionally substituted with a phenyl; M1 is CR49, where R49 is H; M2 is CR50, where R50 is H; R38 is H, C1-C6alkyl, substituted with a phenoxy group; C3-C6cycloalkylC1-C6alkyl; arylC1-C6alkyl, optionally substituted with 1 or 2 substitutes selected from a group comprising C1-C6alkyl, C1-C6alkoxy, C1-C6alkoxycarbonyl, carboxyl, N-methylamido, hydroxy, C1-C6alkoxyC1-C6alkoxy, C1-C6alkylthio, C1-C6alkylsulphanyl, cyano, halogen, perfluoroC1-C6alkyl, nitro, formyl, hydroxyC1-C6alkyl and amino, wherein the aryl moiety is a phenyl or naphthyl; and heteroarylC1-C6alkyl, where the heteroaryl moiety is pyridinyl, optionally substituted with 1 or 2 groups selected from C1-C6alkoxy or hydroxyC1-C6alkyl, pyrazolyl or isoxazolyl, substitute with 1 or 2 C1-C6alkyl groups; R47 and R48 is C1-C6alkyl. The invention also relates to specific compounds, a method of reducing or weakening bitter taste, a composition of a food/non-food product or beverage or drug for reducing or lightening bitter taste and a method of producing a compound of formula (I).

EFFECT: obtaining novel compounds which are useful as bitter taste inhibitors or taste modulators.

37 cl, 6 dwg, 12 tbl, 186 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and provides an external therapeutic agent for the patients suffering atopic dermatitis comprising zinc pyrithione, urea, glyceryl stearate, emulsion wax, triethanolamine, cocoa butter, corn oil, mineral oil, caprylic and capric acid triglycerides, cyclomethicone, glycerine, carbopol, peach flavour, and drinking water, and the ingredients in the agent are taken in a certain mass ratio.

EFFECT: invention provides good tolerability, comfortable use, avoidance of side effects, recovery of the physiological properties of the skin.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely endocrinology, and concerns predicting the clinical effectiveness in diabetic polyneuropathy in the patients suffering type 2 diabetes and dyslipidemia. That is ensured by evaluating the intensity of diabetic polyneuropathy manifestations taking into account neuropathic dysfunctional score, evaluating triglycerides and glycolised blood hemoglobin before the treatment; the derived data are used to specify a therapeutic approach followed by further estimation of a probability of a successful correction of diabetic polyneuropathy by formula P=111+e(0,991,78Z), wherein e is the basis of hyperbolic logarithm e=2.72; Z is a regression coefficient calculated by formula 7=4.56-0.05*"ДлСД"-0.02*IntDPN-0.05*TG-0.53*HbAlc+0.14TherApp; if the value P is 0.7 or more, the successful correction of DPN is predicted in the patients, and the value P less than 0.7 requires the therapeutic approach to be changed.

EFFECT: method provides the improved clinical effectiveness ensured by the individual therapeutic approach based on the lipid and carbohydrate metabolism of a specific patient.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents an agent for local treatment of periodontal diseases, on the basis of organosilicone gycerohydrogel Si(C3H7O3)4·6C3H8O3·24H2O, containing therapeutic supplements, differing by the fact that the therapeutic supplements are presented by ketoprofen and methyluracil in the following proportions, wt %: ketoprofen - 0.5 - 1.0; methyluracil - 1.0 - 1.5; organosilicone gycerohydrogel Si(C3H7O3)4·6C3H8O3·24H2O - up to 100.

EFFECT: invention provides creating the effective agent applicable in the integrated therapy for treating the inflammatory periodontal diseases.

6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely represents composition, which contains mixture of particles of hydrophobic silicon dioxide aerogel, which have specific area of surface per weight unit (Sw) in range from 500 to 1500 m2/g and size, expressed in form of volume mean diameter (D[0.5]), in range from 1 to 1500 mcm, and at least one first linear silicone oil, which has viscosity higher than 50 mm2/s, and at least second and third linear silicone oils, and each of them has viscosity lower than or equal 50 mm2/s.

EFFECT: mixture of particles of silicon dioxide aerogel and linear oils provides possibility of obtaining compositions, which provide comfort and smoothness of skin after application and have dullness and "soft focus"-adding properties.

23 cl, 8 ex

Up!